IPP Bureau
US & UK reach historic pharma pricing pact
By IPP Bureau - December 03, 2025
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
AbbVie’s Atogepant shows breakthrough results for acute migraine relief
By IPP Bureau - December 03, 2025
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Belite Bio reports landmark phase 3 success for Stargardt Disease therapy
By IPP Bureau - December 03, 2025
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
LENZ Therapeutics, Lotus Pharmaceutical submit NDA for presbyopia treatment in Korea
By IPP Bureau - December 03, 2025
Presbyopia, the age-related loss of near vision, could soon be treated successfully
WHO urges rapid expansion of new HIV prevention tools amid funding crisis
By IPP Bureau - December 03, 2025
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Cleveland Diagnostics’ IsoPSA test for prostate cancer detection gains FDA approval
By IPP Bureau - December 03, 2025
Now a test that offers new precision in prostate cancer detection
FDA accepts Wockhardt's NDA for breakthrough antibiotic Zaynich
By IPP Bureau - December 02, 2025
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Data deluge at ASH: Bristol Myers Squibb showcases breakthroughs across blood cancers
By IPP Bureau - December 02, 2025
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Lilly slashes prices on Zepbound vials to expanding access to obesity treatment
By IPP Bureau - December 02, 2025
Patients can now get the starting 2.5 mg dose for $299 per month
Bayer welcomes US Solicitor General’s support as Supreme Court weighs Roundup case
By IPP Bureau - December 02, 2025
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
Sun Pharma introduces Ilumya in India for treatment of plaque psoriasis
By IPP Bureau - December 01, 2025
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Lupin receives FDA approval for biosimilar Armlupeg
By IPP Bureau - December 01, 2025
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Roche expands Veeva partnership with global rollout of AI-driven Vault CRM
By IPP Bureau - December 01, 2025
Roche says the move marks a step forward in its digital transformation strategy
OSR Holdings moves towards major licensing deal for oral cancer immunotherapy
By IPP Bureau - December 01, 2025
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
LANXESS unveils next-gen biosecurity solutions for Indian poultry market at Poultry Expo
By IPP Bureau - December 01, 2025
LANXESS Biosecurity Solutions aims to deliver “advanced disinfection and hygiene solutions to support Indian farmers in maintaining healthier and safer farm environments
